PIM
RXRX icon

Platinum Investment Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Platinum Investment Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-395,954
Closed -$2.09M – 127
2025
Q1 		$2.09M Sell
395,954
-337,057
-46% -$2.46M 0.12% 51
2024
Q4 		$4.96M Buy
733,011
+546,929
+294% +$3.68M 0.29% 37
2024
Q3 		$1.23M Sell
186,082
-209,591
-53% -$1.5M 0.06% 75
2024
Q2 		$2.97M Sell
395,673
-1,404,796
-78% -$12.3M 0.12% 55
2024
Q1 		$18M Sell
1,800,469
-473,495
-21% -$5.27M 0.72% 23
2023
Q4 		$22.4M Sell
2,273,964
-61,168
-3% -$436K 0.91% 24
2023
Q3 		$17.9M Sell
2,335,132
-376,016
-14% -$3.75M 0.7% 28
2023
Q2 		$20.3M Sell
2,711,148
-59,303
-2% -$415K 0.7% 31
2023
Q1 		$18.5M Buy
2,770,451
+60,112
+2% +$477K 0.64% 31
2022
Q4 		$20.9M Buy
2,710,339
+458,368
+20% +$4.49M 0.8% 27
2022
Q3 		$24M Sell
2,251,971
-283,651
-11% -$2.87M 1% 25
2022
Q2 		$20.6M Buy
2,535,622
+399,018
+19% +$2.67M 0.78% 27
2022
Q1 		$15.3M Buy
2,136,604
+692,741
+48% +$7.36M 0.47% 37
2021
Q4 		$24.7M Buy
1,443,863
+782,160
+118% +$14.7M 0.69% 27
2021
Q3 		$15.2M Buy
661,703
+189,151
+40% +$5.36M 0.43% 36
2021
Q2 		$17.2M Buy
+472,552
New +$14M 0.4% 40

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Platinum Investment Management's RXRX Position: Q2 2025 in Review

Platinum Investment Management sold out of Recursion Pharmaceuticals (RXRX) in Q2 2025, closing a stake of 395,954 shares — an estimated $2.09M sold.

Platinum Investment Management first reported a position in RXRX in Q2 2021 and held it in 16 quarters. The position peaked at $24.7M in Q4 2021. 332 funds tracked by Wall St. Rank hold RXRX as of Q2 2025.

  • Platinum Investment Management reported no remaining Recursion Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Platinum Investment Management sold 395,954 Recursion Pharmaceuticals shares in Q2 2025, an estimated $2.09M.
  • Platinum Investment Management first reported a position in Recursion Pharmaceuticals in Q2 2021 and held it in 16 quarters.
  • Platinum Investment Management's Recursion Pharmaceuticals position peaked at $24.7M in Q4 2021.
  • 332 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2025.

Based on Platinum Investment Management's 13F filing for Q2 2025, filed 21 Jul 2025.